Back

Real-world insights into treatment modalities and emerging myosin inhibitor therapy for hypertrophic obstructive cardiomyopathy: early findings from the German REDUCE-Registry

31 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Left ventricular outflow tract obstruction Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Leni Katharina Seuthe

Cologne University Hospital - Heart Center, Cologne (Germany)

6 More presentations in this session

Presentation thumbnail
Multicenter study on the effect of Mavacamten on pulmonary artery systolic pressure derived from echo-doppler in obstructive hypertrophic cardiomyopathy
Doctor M. Gegenava (Tbilisi, GE)
Abstract Slides Video
Presentation thumbnail
Comparison of characteristics and outcomes of patients with obstructive vs. non-obstructive hypertrophic cardiomyopathy in a cohort from a referral center in colombia
Doctor J. Orozco Burbano (Medellin, CO)
Abstract Slides Video
Presentation thumbnail
Outcomes of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in Japan
Doctor T. Yamaguchi (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Genetic, echocardiographic and clinical determinants of mitral valve abnormalities in hypertrophic cardiomyopathy
Miss H. Panholzer (Graz, AT)
Abstract Slides Video
Presentation thumbnail
Common pathophysiological mechanism of SAM and mitral regurgitation in HOCM
Associate Professor Z. Wang (Hangzhou, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Left ventricular outflow tract obstruction

The Event

Event poster

ESC Congress 2025

31 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Real-world symptom and echocardiographic improvement in obstructive HCM patients treated with mavacamten: evidence of favorable disease modification
thumbnail
Congress Presentation
Spotlight on cardiac myosin inhibition
thumbnail
Congress Session
Contemporary management of hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources